Table 2—

Effectiveness and safety profiles during rosiglitazone therapy*

Category and variablesAt baselineAt endP value
Effectiveness profiles
    Diabetic parameters
    Fasting glucose level (mg/dl)142 ± 21102.8 ± 24<0.01
    A1C (%)8.6 ± 0.67.1 ± 0.5<0.01
    Lipid profiles
    Total cholesterol (mg/dl)178 ± 42.1174 ± 46.50.589
    Triglyceride (mg/dl)194 ± 112.5168 ± 880.037
    HDL cholesterol (mg/dl)36 ± 1638.6 ± 7.80.217
    LDL cholesterol (mg/dl)110 ± 23118.2 ± 140.141
    Inflammatory biomarkers: human serum CRP (mg/l)4.22 ± 1.23.24 ± 0.90.092
Safety parameters
    Kt/V1.62 ± 0.261.58 ± 0.310.403
    Systolic blood pressure (mmHg)134 ± 16128 ± 210.061
    Diastolic blood pressure (mmHg)86 ± 1488 ± 160.407
    Weight (kg)57.4 ± 10.660.2 ± 11.80.121
    Ultrafiltration (kg/per hemodialysis session)2.07 ± 1.63.2 ± 1.2<0.01
CTR (%)48.2 ± 5.650.4 ± 6.20.0213
Albumin (g/dl)3.8 ± 0.33.9 ± 0.40.081
Blood urea nitrogen (mg/dl)78 ± 1676 ± 120.381
Creatinine (mg/dl)8.6 ± 1.68.8 ± 1.40.395
AST (IU/l)19.2 ± 5.418.6 ± 4.30.443
ALT (IU/l)13.4 ± 4.811.2 ± 5.70.097
Alkaline phosphatase (IU/l)75 ± 8.679 ± 9.40.115
  • Data are means ± SD.

  • *

    * Effectiveness profiles (n = 72) include effects on diabetes control and changes in lipid profiles and inflammatory biomarkers during rosiglitazone therapy. Safety parameters (n = 78) indicate the safety profile recorded during rosiglitazone therapy.

  • Weight, expressed as midweek predialysis weight (dry weight).

  • The CTR is the maximum transverse diameter of the heart divided by the greatest internal diameter of the thoracic cage (from inside of rib to inside of rib).